SCHEMBL1641910

SCHEMBL1641910

Cc1cc2[nH]c(C(=O)O)c(C)c2c(C)c1Oc1ccc(O)c(Cc2ccc(F)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 15/20 0.54
▸ THRA P10827 14/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642681 0.83 THRA (0.52) THRBTHRA
SCHEMBL7082561 0.83 THRA (0.52) THRBTHRA
SCHEMBL1642728 0.80 THRB (0.45) THRBTHRA
SCHEMBL1642997 0.80 THRA (0.54) THRBTHRA
SCHEMBL6273680 0.80 THRB (0.51) THRBTHRA
SCHEMBL7082555 0.79 THRA (0.54) THRBTHRA
SCHEMBL7082553 0.77 THRA (0.47) THRBTHRA
SCHEMBL6268671 0.77 THRA (0.50) THRBTHRA
SCHEMBL1640873 0.77 THRA (0.73) THRBTHRA
SCHEMBL4964919 0.75 THRB (0.72) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098303-A1 Method of promoting nail growth using thyromimetic compounds DOHERTY NIALL S 2011-04-28 — — US claimed
EP-1297833-B1 Indole carboxylic acids as thyroid receptor ligands PFIZER PROD INC (US) 2005-12-21 — — EP claimed
WO-2004047827-A1 METHOD FOR PROMOTING NAIL GROWTH USING THYROMIMETIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2004-06-10 — — WO claimed
US-6723744-B2 FOR THERAPY OF OBESITY, OVERWEIGHT CONDITION, HYPERLIPIDEMIA, GLAUCOMA, CARDIAC ARRHYTHMIAS, SKIN DISORDER, THYROID DISEASE, HYPOTHYROIDISM, THYROID CANCER, DIABETES, ATHEROSCLEROSIS, HYPERTENSION, CORONARY HEART DISEASE, HYPERCHOLESTEREMIA PFIZER, INC. 2004-04-20 — — US claimed
US-20030078289-A1 Indole carboxylic acids as thyroid receptor ligands ASPNES GARY E (US) 2003-04-24 — — US claimed
EP-1297833-A1 Indole carboxylic acids as thyroid receptor ligands Pfizer Products Inc. (US) 2003-04-02 — — EP claimed
US-20110098303-A1 Method of promoting nail growth using thyromimetic compounds DOHERTY NIALL S 2011-04-28 — — US disclosed
EP-1297833-B1 Indole carboxylic acids as thyroid receptor ligands PFIZER PROD INC (US) 2005-12-21 — — EP disclosed
WO-2004047827-A1 METHOD FOR PROMOTING NAIL GROWTH USING THYROMIMETIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2004-06-10 — — WO disclosed
US-6723744-B2 FOR THERAPY OF OBESITY, OVERWEIGHT CONDITION, HYPERLIPIDEMIA, GLAUCOMA, CARDIAC ARRHYTHMIAS, SKIN DISORDER, THYROID DISEASE, HYPOTHYROIDISM, THYROID CANCER, DIABETES, ATHEROSCLEROSIS, HYPERTENSION, CORONARY HEART DISEASE, HYPERCHOLESTEREMIA PFIZER, INC. 2004-04-20 — — US disclosed
US-20030078289-A1 Indole carboxylic acids as thyroid receptor ligands ASPNES GARY E (US) 2003-04-24 — — US disclosed
EP-1297833-A1 Indole carboxylic acids as thyroid receptor ligands Pfizer Products Inc. (US) 2003-04-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098303-A1 Method of promoting nail growth using thyromimetic compounds TPO, POLR1C, TYR THRB 29/4885THRA 21/4885
US-20030078289-A1 Indole carboxylic acids as thyroid receptor ligands THRA, MC1R, THRB THRB 3/4885THRA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback